Commercializing Living Therapies with CCRM

Featuring:Jacki Jenuth, PhD, Partner and COO, Lumira VenturesRobin Quirk, PhD MBA, Vice President, Technology Sourcing and Venture Development, CCRM***In this episode, we explore the dynamics of venture capital (VC) and company creation with Jacki Jenuth, Partner and COO, Lumira Ventures, and Robin Quirk, Vice President, Technology Sourcing and Venture Development, CCRM. The conver

Featuring:Michael Rosu-Myles, PhD, Executive Director, Health CanadaJosephine Lembong, PhD, Senior Manager, Science and Industry Affairs, Alliance for Regenerative Medicine***Currently, there are more than 2,000 cell and gene therapies in clinical trials worldwide. With a goal of ensuring that safe and quality products are approved for use by patients, regulators determine whether

Featuring:Sonia Sennik, Executive Director, Creative Destruction LabGlenn MacLean, Director, Technology Sourcing and Venture Development, CCRM***In many science-oriented fields, including regenerative medicine and advanced therapies, researchers and company founders often require additional support and expertise to successfully commercialize their discoveries. With a mission of enh

Featuring:Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy CatapultMichael May, PhD, President and Chief Executive Officer, CCRM***Public-private partnerships are collaborations between government agencies and private-sector companies. In this interview, Matthew Durdy, CEO, Cell and Gene Therapy Catapult, and Michael May, President and CEO, CCRM, explain how these coll

Featuring:Matthew Miller, B.M.Sc., PhD, Director, Michael G. DeGroote Institute for Infectious Disease Research; Co-Director, Canadian Pandemic Preparedness Hub (CP2H), McMaster University Patrycja Thompson, PhD, Director, Strategy & Operations, the Canadian Hub for Health Intelligence & Innovation in Infectious Diseases (HI3), University of Toronto***The COVID-19 pandemic

Featuring:Mamatha Bhat MD, MSc, PhD, FRCPCHepatologist & Co-Lead of Transplant AI initiative (TAI), Ajmera Transplant Program Scientist, Toronto General Hospital Research Institute, University Health NetworkAssociate Professor, Division of Gastroenterology & HepatologyDirector, Clinician-Scientist Training Program (CSTP), Department of Medicine, University of TorontoPartner

Featuring:Tom Whitehead, Co-Founder, Emily Whitehead Foundation. Courtney Horvath, PhD, Global Head of Strategy, Planning & Operations, Translational Medicine, Novartis. In this episode, we hear from two parents who supported their children through cancer treatments. Listeners will hear their unflinching accounts of what the children went through, underlining the urgent need fo

Featuring:Dr. Joerg Krueger, Medical Director, CAR T-Cell Program, The Hospital for Sick Children. Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine.Our guests discuss the future of CAR T-cell therapies, in a conversation covering autologous and allogeneic CAR T therapies. Drs. Krueger and Levine sha

Featuring:Mark Taylor, Director of Commercialization, University Health Network Dr. Irja Elliott Donaghue Technical & IP Specialist and Patent Agent, Notch TherapeuticsIn the past, there was little evidence to challenge the idea that if a therapeutics developer did not hold a patent, it did not have anything to commercialize. In this episode, guests outline how the regenerative

Featuring:Dr. Dolores Baksh, CEO of TAAV Biomanufacturing SolutionsSusan Nichols, Chief Business Officer at ViroCell BiologicsAs the cell and gene therapy industry continues to grow rapidly, Dolores Baksh and Susan Nichols emphasize the importance of nurturing a new workforce equipped with the skills to pivot and persevere—crucial qualities for the industry to grow. Join our gues